Indian pharma company Lupin Limited has launched Formoterol Fumarate Inhalation Solution, 20 mcg/2 mL per Unit-Dose Vial in the US market.

The product is a generic version of Mylan Specialty’s Perforomist Inhalation Solution, 20 mcg/2 mL, which is used for the treatment of asthma and prevention of bronchospasm in asthma patients.

As per data from IQVIA MAT September 2022, the estimated annual sales of Formoterol Fumarate Inhalation Solution in the US are $268 million.

Separately, Lupin announced that its Brazilian subsidiary MedQuímica Indústria Farmacêutica has acquired rights to nine drugs from BL Indústria Ótica, a subsidiary of Bausch Health Companies.

  Asthma, bronchospasm, Formoterol Fumarate, Lupin, Mylan Specialty, Perforomist Inhalation Solution, USA